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Abstract 
 
Background: This study analyzes the therapeutic effects of intravenous infusion of iloprost in wound healing, 
healing of the amputation stump wound, improvement in intermittent claudication and prevention of major ampu-
tation in patients with Buerger’s disease. 
 
Methods: In a prospective study, 19 patients with known Buerger’s disease, received intravenous iloprost infu-
sion, 6 hours per day for 10 days. Iloprost with a dose of 0.5-2 ng/kg/min according to the patients’ tolerance and 
using cardiac monitoring during the whole infusion period was administered for 6 hours/day using saline solution. 
Patients with larger wounds underwent simultaneous transmetatarsal or Ray amputation of the involved toe(s). 
All patients were discharged after 10 days. Patients were followed to detect their healing changes. 
 
Results: Nineteen patients, 19-55 years old received 0.5-2 ng/kg/min iloprost intravenously for 6 hours/day for 
10 days. During this period, there was relative improvement in resting pain, but no significant amelioration was 
noticed in wound healing. In a 2 years follow-up, 14 patients showed a complete healing of the amputation stump 
and increased distance of walking without any pain. Some previous candidates of major amputation did not need 
amputation anymore. Five patients (26%) did not respond to therapy. 
 
Conclusion: Although Buerger’s disease patients who were under iloprost therapy, may not show significant 
changes in wound healing during treatment and at discharge, late results have proved that iloprost infusion is 
promising in improving wound healing and claudication and preventing major amputations. 
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Introduction 
 
Buerger’s disease or thromboangiitis oblitrans, com-
prises 0.5-15% of obstructive vascular diseases in 
western countries and 9-30% in eastern ones.
1,2,3 This 
disease is a segmental non-atherosclerotic inflamma-
tory process which mostly involves medium and 
small sized arteries and veins in lower and upper ex-
tremities. It is categorized as vasculitis; patients are 
usually young smoker men and its prevalence in wom-
en is reported as 1-2%.
4,5 There is a close relationship 
with smoking; 95% of the patients are smokers. 
Its etiology is not known completely, but a strong 
correlation with use of every type of smoking, even 
non-smoked tobacco,
6,7 has proposed the theory of 
sensitivity to some components of tobacco. It is not 
clear whether tobacco is a cause or a promoting fac-
tor, yet the active phase of the disease is related to 
higher level of smoking. Patients with Buerger’s dis-
ease are young to middle-aged who have a history of 
smoking and presents with pain while walking and in 
severe cases at rest, upper and lower limb discoloration 
and gangrene. As the possibility of vascular bypass is 
usually nil, the consequence of their disease is limb am-
putation especially in the lower extremities. Adar and 
colleagues showed that there is an increased cellular 
sensitivity to collagen types I and II in these patients 
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when compared with normal individuals.
7 Endothelin-
dependent vascular relaxation in peripheral vasculature 
is impaired in patients with Buerger’s disease.
8 
Iloprost (Ilomedin, Alprostadil) is the synthetic 
analogue of prostaglandin 12 (PG 12). Due to the rap-
id clearance from the central compartment, it is rou-
tinely administered as an intravenous infusion.
9 It is 
one of the hemorrheologic factors
10-12 which through 
vasodilatation
13 and prevention of platelet granule 
release and thromboxane A2 synthesis
14 increases the 
chance of delayed amputation avoidance when used 
in Buerger’s disease. 
 
 
Materials and Methods 
 
Nineteen patients with the diagnosis of Buerger’s dis-
ease (from 6 months to 10 years prior to this presenta-
tion) who were all males and had a history of smok-
ing, with presenting symptoms of burning pain of the 
lower extremities, intermittent claudication, toe(s) 
discoloration or impaired healing of the amputation 
stump, entered the study. Their age range was 19-55 
years (mean: 38). Involved limbs were examined for 
the wound characteristics and its locations; all four 
extremities were examined and a Digital Subtraction 
Angiography (DSA) of the involved limb was done. 
Routine lab tests and electrocardiography was 
checked for all patients. After explaining different 
treatments, the advantages and disadvantages of each 
and cost of the treatment with iloprost, and also after 
patients gave the informed consent, they were known 
as eligible for the study. First, the highest tolerable 
dose of iloprost within the range of 0.5-2 ng/kg/min 
was determined for each patient; this maximum dose 
was given as continuous intravenous infusion of ilo-
prost in normal saline for 6 hours per day for 10 days 
(with tight control of vital sign and cardiac monitor-
ing during the infusion). 
An electrocardiography was done on termination 
of each infusion. In those patients who needed an 
amputation, a Ray or a transmetatarsal amputation of 
the toe(s) was done within the same period. The pa-
tients were discharged after 10 days. Antibiotics were 
given only to those patients with accompanying cellu-
lites. Patients were followed for 2 years. The response 
criteria were complete wound healing, no further need 
for sympathectomy, improvements of claudication 
and significant increase in painless walking. 
 
 
Results 
 
Among 19 patients, one patient died 2 months after 
discharge from the hospital and was excluded. Pa-
tients were in the age range of 19-55 years (mean: 38) 
and 4 of them were above 50 years old. The rest were 
in their third and forth decades. They were from dif-
ferent locations of Iran and had a history of this ill-
ness for 6 months to 10 years. Their chief complaints 
varied from burning rest pain in the lower extremities, 
to discoloration of the limbs, intermittent claudica-
tion, and toe necrosis or amputation stump gangrene 
(Figure 1). 
 
Fig. 1: Patient with Buerger’s disease before initiation of the treatment. Afsharfard et al. 
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In 9 patients, popliteal pulse was not palpable in 
the affected limb. All patients had femoral pulses, but 
even in those with palpable popliteal pulse, no distal 
pulse could be detected. DSA was done in all patients 
and it was always consistent with Buerger’s vasculitis 
and non-reconstructable vessels. Patients had been 
receiving dipyridamole and pentoxiphyllin for months 
to years prior to this study, yet their complaints had 
persisted. Eleven patients had become addicted to 
different types of opioid analgesics due to persistent 
severe pain. Eight patients (42%) had a history of uni- 
or bilateral lumbar sympathectomy and one had un-
dergone thoracic sympathectomy previously. An in-
terval of at least four months was mandatory after 
sympathectomy and before bringing the patients into 
this study. This was supposed as the needed time for 
revelation of the complete effect of sympathectomy. 
All patients had a history of smoking between 6 
months to several decades. Five patients had a past 
history of below knee amputation in one of the lower 
extremities. In those with toe gangrene, Ray amputa-
tion of the toe was done simultaneously with the initia-
tion of iloprost infusion. Two patients had successful 
skin graft placement during treatment with iloprost.  
After termination of iloprost infusion (10 days of 
treatment), patients were discharged. The signs and 
symptoms had some changes after 10 days: signifi-
cant reduction of rest pain, decreased need to narcotic 
pain- killers and mild improvements of leg edema and 
redness. Patients felt more warmth in their legs, but 
there was not a dramatic change in the wound healing 
after 10 days. An ECG was done for each patient as a 
base on day 1 and every day after termination of ilo-
prost infusion. Three patients, who developed sinus 
tachycardia once after infusion, responded to medica-
tions and tolerated further infusions the following days. 
Liver function tests, serum biochemistry, urinaly-
sis and coagulation tests were done for the patients on 
a daily basis. We encountered two cases of elevated 
alkaline phosphatase, one slightly and the other twice 
the base line. No other change in the tests was detect-
ed. In the 2 years follow-up, 5 patients did not re-
spond to this treatment and had not improvements in 
wound healing. One of these cases underwent lumbar 
sympathectomy and transmetatarsal amputation of the 
first toe; while the rest 4 failures, who had undergone 
lumbar sympathectomy before iloprost trial, under-
went below knee amputation. 
In 13 patients (72.2%), an acceptable response to 
iloprost infusion was detected in form of healed 
wounds, improvements in intermittent claudication and 
pain relief in distal lower extremities (Figure 2 and 
Figure 3). All cases were able to successfully stop 
smoking.  
 
 
Fig. 2: Same patient, 45 days after iloprost treatment 
initiation. 
 
 
Fig. 3:  Twenty months follow-up of the patient in 
Figure 1. 
 
 
Discussion 
 
Drugs effective on erythrocyte flexibility, agents act-
ing on platelets, non-steroidal anti-inflammatory 
drugs (NSAIDs) and vascular reconstruction are 
among several therapeutic methods for Buerger’s dis-
ease. The base of treatments is ceasing smoking. All 
other treatments are in the second line. If the patient Iloprost infusion in wound healing 
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does not have any wound in the limb when he stops 
smoking, he will usually become asymptomatic. 
Iloprost, a synthetic analogue of PG12, acts 
through vasodilatation and effects on platelets, pre-
venting their granule release; it can improve symp-
toms and prevent major amputations in patients with 
Buerger’s disease. In this study, although the patients 
had not showed significant improvements in wound 
healing upon discharge, delayed effects of iloprost in 
the form of healed amputation stump wounds and 
avoidance of major amputations were detected within 
a follow-up of 2 years.
15,16 
This study was performed on 19 patients. As 
Buerger‘s disease is known to be more prevalent in 
Iran compared to western countries, we recommend 
that further multi-center studies be performed on 
larger numbers of patients. 
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